



## Cell Stress, Canonical and Non-Canonical Cell Death Modalities by Marine Natural Compounds and Derivatives

Guest Editor:

**Prof. Dr. Marc Diederich**

Department of Pharmacy,  
College of Pharmacy, Seoul  
National University, Building 29  
Room 223, 1 Gwanak-ro, Gwanak-  
gu, Seoul 08826, Republic of  
Korea

Deadline for manuscript  
submissions:

**closed (10 November 2019)**

### Message from the Guest Editor

Dear Colleagues,

This Special Issue will focus on the discovery of novel cytostatic and cytotoxic agents of marine origin, with a focus on the cellular mechanisms the lead to cell cycle inhibition, cell stress, and diverse cell death modalities.

By now, programmed cell death modalities that use non-canonical pathways different from the well-established apoptotic mechanisms are beginning to be better understood. Considering that many cancer types can develop resistance mechanisms against apoptotic cell death, pharmacologically active compounds, in particular of marine origins could be new sources and provide ideas for drugs triggering cell death modalities including controlled necrosis, parthanatos, ferroptosis and more.

Interestingly, compounds able to trigger stress leading to ER stress or autophagic stress responses were recently described also to trigger hallmarks of immunogenic cell death when dying cells liberate so-called danger associated molecular patterns. Marine compounds remain largely unexplored for their capacities to activate such cell death modalities, and innovating contributions in this field are highly welcome.

Prof. Dr. Marc Diederich  
*Guest Editor*



[mdpi.com/si/16911](https://mdpi.com/si/16911)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Bill J. Baker

Department of Chemistry,  
University of South Florida, 4202  
E. Fowler Ave., CHE 205, Tampa,  
FL 33620-5250, USA

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

## Contact Us

Marine Drugs Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/marinedrugs](http://mdpi.com/journal/marinedrugs)  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)  
X@Marine\_Drugs